The FDA has approved a new drug called Zoladex (goserelin) to treat prostate cancer. It is used in two ways. For men with early stage prostate cancer (stage T2b to T4), Zoladex is given along with another drug called flutamide. Treatment starts 8 weeks before radiation therapy and continues during radiation. For men with advanced prostate cancer that has spread, Zoladex is used as palliative treatment to help relieve symptoms and slow the cancer's growth.
Zoladex works by lowering certain hormones that can fuel prostate cancer. It is given as a small implant under the skin. There are two doses: a 3.6 mg implant given every month and a 10.8 mg implant given every 12 weeks. The longer acting dose offers a more convenient schedule for patients and doctors.
The approval was based on studies that showed Zoladex works as well as surgical removal of the testicles (orchiectomy) in controlling the cancer. The 10.8 mg dose was shown to be pharmacodynamically equivalent to the 3.6 mg dose.
This approval gives men with prostate cancer another treatment option. However, it is important to remember that every patient is different. If you or a loved one has prostate cancer, talk to your doctor about whether Zoladex might be right for you. Your doctor can explain the benefits and risks based on your specific situation.